media – Page 665 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Alexion and Halozyme Enter License Agreement for ENHANZE Technology

Alexion Pharmaceuticals, Inc. (ALXN) and Halozyme Therapeutics, Inc. (HALO) announced a collaboration and license agreement that enables Alexion to use Halozyme’s ENHANZE® drug-delivery technology in the development of subcutaneous formulations for their portfolio of products. The agreement provides Alexion with the opportunity for exclusive development of up to four targets, including a next generation subcutaneous formulation of ALXN1210 (ALXN1210 SC), the company’s investigational long-acting C5 complement inhibitor, to potentially further extend the dosing interval of ALXN1210 SC to once every two weeks or once per month.
- Source: news.alexionpharma
- 550
- December 12, 2017
ALXN1210 formulation inhibitor Market Views
Philippines halts sale of Sanofi’s dengue vaccine

The Philippines has suspended the sale and distribution of Sanofi’s dengue vaccine, authorities said on Tuesday, after the French pharmaceutical giant last week warned it could worsen symptoms for people who had not previously been infected.
- Source: Thenews
- 835
- December 12, 2017
Dengvaxia vaccine Sanofi’s dengue vaccine
Type 2 diabetes may be reversible suggests new research

A UK trial study has found that type 2 diabetes could potentially be reversed through weight loss, and with the long-term support of a medical professional.
- Source: msn.com
- 588
- December 12, 2017
diabetes weight loss
Health2Sync raises $6M to expand its diabetes tracking and management service in Asia

Health2Sync, a Taiwan-headquartered company that offers a diabetes tracking service, has closed a $6 million Series B round aimed at expanding its business in Japan and other markets in Asia.
- Source: drugdu
- 530
- December 11, 2017
diabetes diabetes tracking service Health2Sync Series
Stratasys Releases Line of Custom Built 3D Printed Anatomy Models

Stratasys, one of the big 3D printing companies, has announced the release of its new BioMimics line of 3D printed human anatomy models. The products are designed to be used in clinical training and to help design and test new medical devices.
- Source: medgadget
- 496
- December 11, 2017
anatomy Market Views model vascular
Sage Therapeutics Erupts as Depression Drug Wows in Mid-Stage Study

Shares of Sage Therapeutics have shot up more than 75 percent this morning after the company announced positive topline results for its Phase II treatment for patients with moderate to severe major depressive disorder (MDD).
- Source: Biospace
- 561
- December 11, 2017
Clinical Trials MDD SAGE-217
Carmot Enters a Multi-Year Drug Discovery Collaboration With Amgen

Carmot Therapeutics, (Berkeley, CA) announced that it has entered into a multi-year drug discovery collaboration and licensing agreement with Amgen (Thousand Oaks, CA). As part of the agreement, Carmot will apply its proprietary lead-identification technology, Chemotype Evolution, to discover and advance novel drug leads intended for the treatment of Parkinson’s disease and other selected disease areas.
- Source: Bestsellermagazine
- 604
- December 11, 2017
Amgen Market Views Parkinson’s disease
How to Establish A Good Relationship with Your Suppliers

As an international trade company, it’s necessary to establish good relationship with suppliers since our goal is to collaborate with them for support in marketing and product supply.
- Source: Ddu
- 668
- December 11, 2017
foreign trade professional friendships
Gilead Sciences to Acquire Cell Design Labs for $567 Million

Gilead Sciences, Inc. GILD and its newly acquired cell therapy subsidiary -Kite Pharma- announced that they have inked an agreement to acquire Cell Design Labs, Inc. for $567 million. Gilead will also acquire 12.2% of Cell Design shares which are owned by Kite Pharma.
- Source: qc.nasdaq
- 507
- December 11, 2017
Apple’s First Medical Study Signals Broader Health Ambitions

Medical researchers are increasingly turning to mobile devices such as smartphones and watches as a way to monitor patients in trials, an approach they hope improves participation and accuracy but that also has limitations.
- Source: wsj
- 661
- December 11, 2017
heart rhythms mobile device Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.